Key result
Preoperative aspirin use significantly reduced the occurrence of non-valvular atrial fibrillation at 3 months after coronary bypass surgery compared to no treatment (5.5% vs 24.3%, P<0.05).
Why the study?
Postoperative non-valvular atrial fibrillation is common after coronary surgery and increases hospital costs and length of stay, prompting investigation into whether preoperative aspirin prevents it.
Does preoperative aspirin prevent non-valvular atrial fibrillation in patients undergoing coronary artery bypass grafting?
Cohort (n=572)
Does preoperative aspirin prevent non-valvular atrial fibrillation in patients undergoing coronary artery bypass grafting?
Absolute Event Rate: 5.5% vs 24.3%
p-value: p=< .05
Preoperative administration of aspirin significantly reduces the incidence of postoperative non-valvular atrial fibrillation and associated hospital costs in patients undergoing coronary artery bypass grafting.
No takes yet. Share an insight, caveat, or question.
May warrant preoperative aspirin consideration before CABG; observational data leaves open need for RCT confirmation.
Erkut et al. (2019) conducted a cohort in Coronary artery bypass grafting (n=572). Aspirin vs. No anti-aggregant treatment was evaluated on Occurrence of non-valvular atrial fibrillation (p=< .05). Preoperative aspirin use significantly reduced the occurrence of non-valvular atrial fibrillation at 3 months after coronary bypass surgery compared to no treatment (5.5% vs 24.3%, P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: